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Objectives

Results

To examine whether it is more efﬁcacious to commence
exercise medicine in men with prostate cancer at the onset of
androgen-deprivation therapy (ADT) rather than later on
during treatment to preserve bone and soft-tissue
composition, as ADT results in adverse effects including:
reduced bone mineral density (BMD), loss of muscle mass,
and increased fat mass (FM).

There was a signiﬁcant time effect (P < 0.001) for whole body,
spine and hip BMD with a progressive loss in the IMEX and DEL
groups, although lumbar spine BMD was largely preserved in the
IMEX group at 6 months compared with the DEL group ( 0.4%
vs 1.6%). LM, ASM, and muscle density were preserved in the
IMEX group at 6 months, declined in the DEL group at
6 months ( 1.4% to 2.5%) and then recovered at 12 months
after training. FM and trunk FM increased (P < 0.001) over the
12-month period in the IMEX (7.8% and 4.5%, respectively) and
DEL groups (6.5% and 4.3%, respectively).

Patients and methods
In all, 104 patients with prostate cancer, aged 48–84 years
initiating ADT, were randomised to immediate exercise
(IMEX, n = 54) or delayed exercise (DEL, n = 50) conditions.
The former consisted of 6 months of supervised resistance/
aerobic/impact exercise and the latter comprised 6 months of
usual care followed by 6 months of the identical exercise
programme. Regional and whole body BMD, lean mass (LM),
whole body FM and trunk FM, and appendicular skeletal
muscle (ASM) were assessed by dual X-ray absorptiometry,
and muscle density by peripheral quantitative computed
tomography at baseline, and at 6 and 12 months.

Introduction
The use of androgen-deprivation therapy (ADT) as an
adjuvant, neoadjuvant or stand-alone treatment for men with
localised and advanced prostate cancer is accompanied by a

Conclusions
Commencing exercise at the onset of ADT preserves lumbar spine
BMD, muscle mass, and muscle density. To avoid treatmentrelated adverse musculoskeletal effects, exercise medicine should
be prescribed and commenced at the onset of ADT.

Keywords
exercise, androgen-deprivation therapy, #PCSM,
#ProstateCancer

range of adverse effects that impact on a patient’s well-being,
risk of comorbidities, and quality of life [1,2]. Principal
amongst these are the musculoskeletal toxicities of reduced
bone mass [3], leading to osteoporosis and an increased risk
of skeletal fracture [4]; a loss of lean mass (LM) or muscle
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mass leading to sarcopaenia [5]; and a reduced muscle
attenuation or muscle density leading to myosteatosis [6], the
fatty inﬁltration of skeletal muscle resulting in reduced
muscle quality. In addition, these changes are accompanied
by an increase in whole body fat mass (FM) and trunk FM,
which may result in the patient being at an increased risk of
cardiovascular and metabolic complications [7]. In addressing
musculoskeletal toxicities, pharmacological agents in the form
of bisphosphonates can be used to increase bone mineral
density (BMD), although the effects on fracture incidence are
less clear [8] and they are also associated with potential
adverse effects [9]. Similarly, denosumab, a receptor activator
of nuclear factor-jΒ ligand (RANKL) inhibitor, results in an
increase in BMD in men receiving ADT for non-metastatic
prostate cancer and is also associated with a reduction in the
incidence of new vertebral fractures [10]. However, as with
the bisphosphonates, there are potential adverse effects such
as an increase in the incidence and prevalence of
osteonecrosis of the jaw [11], as well as musculoskeletal pain
[10]. Moreover, the loss of muscle mass is not addressed by
these agents nor is muscle quality, and loss of muscle mass
and muscle quality in older and less physically robust patients
may compromise functioning and independence [12].
We and others have demonstrated the effectiveness of
targeted exercise, primarily consisting of resistance and/or
aerobic training, in reversing several ADT-related adverse
effects including: reduced muscle mass and strength [13,14],
physical function [15], aerobic ﬁtness [16], fatigue [17], sexual
health [18], and disease-speciﬁc quality of life [19], in men
on existing ADT regimens including those of a long-term
nature. In contrast, less successful has been the effectiveness
of exercise in reversing the ADT-related increases in FM
[6,14,16] and only a few studies have recently been
undertaken in addressing bone loss in men on existing ADT
regimens with minimal beneﬁt [20,21].
However, these studies have been undertaken with
rehabilitative intent and a more opportune time to intervene
may be when ADT is initiated to mitigate or completely
prevent the adverse effects from hormone suppression
occurring in the ﬁrst place. To this end, we previously
undertook a 3-month exercise trial comprised of resistance
and aerobic training in men commencing ADT and found
that treatment toxicity was signiﬁcantly reduced compared
with those undergoing usual care [22]. In the present study,
we extend those ﬁndings by asking the question: is it more
efﬁcacious to prevent ADT musculoskeletal toxicities from the
outset rather than trying to rehabilitate the patient after the
development of toxicities? The present study reports on the
effects of a year-long randomised trial, in which men
initiating ADT were assigned exercise at the onset compared
to 6 months later on during their treatment for prostate
cancer. Speciﬁcally, we investigated whether the
musculoskeletal toxicities could be prevented by a 6-month
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exercise programme concurrently undertaken with the onset
of ADT. As a result, we implemented an osteogenic exercise
regimen that comprised impact loading activities combined
with resistance and aerobic exercise.

Patients and methods
In all, 219 patients were screened for participation from
August 2013 to April 2015 in Perth, Western Australia, and
their progress through the study is shown in Fig. 1. Potential
participants were referred by invitation of their treating
radiation oncologist/urologist to the study coordinator to
assess eligibility and describe the study. Inclusion criteria
included: beginning treatment for prostate cancer involving
ADT and intending to remain on it for at least the next
6 months, no regular exercise (structured aerobic or
resistance training ≥2 sessions/week) in the past 3 months,
able to walk 400 m, and had obtained medical clearance from
their physician. Exclusion criteria included: prior exposure to
ADT; established metastatic disease; established osteoporosis
[23]; taking medications known to effect bone metabolism,
such as bisphosphonates; acute illness; or any musculoskeletal,
cardiovascular or neurological disorder that could inhibit or
put them at risk from exercising, as determined by their
physician. The study was approved by the Human Research
Ethics Committee, and all participants provided written
informed consent.
Study design
This was a single-blinded randomised controlled trial (RCT;
investigators and testing personnel blinded to group
allocation) with partial crossover, with the primary study
endpoint being BMD [24]. Following familiarisation and
baseline assessments, 104 men were randomly assigned using
a computer random assignment program to either immediate
exercise (IMEX) or delayed exercise (DEL), and stratiﬁed
according to age (≤70 and >70 years) and smoking status
(yes/no). The IMEX group undertook a multicomponent
programme that combined resistance + aerobic + impactloading exercise in the initial 6 months with no formal
intervention in the second 6 months, whilst the DEL group
had 6 months of usual care followed by 6 months of the
identical resistance + aerobic + impact-loading exercise
programme. All participants received standard daily
supplementation with calcium (1000 mg/day) and vitamin D3
(800 IU/day). Measurements were performed at baseline, and
at 6 and 12 months.
Exercise programme
The exercise programme was undertaken thrice weekly in
several exercise clinics in the Perth metropolitan area,
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Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) diagram. ITT, intention-to-treat.

Directly referred by radiation oncologists/urologists and assessed for eligibility (n=219)
Excluded (n = 115)
Ineligible (commenced ADT) (n = 29)
Too far to travel (n = 19)
Declined to participate (n = 17)
Health Issues (n = 13)
No time for training (n = 12)
Holidays (n = 8)
Ineligible (not willing to be randomised) (n = 6)
Randomised (n=104)

Allocated to Delayed Exercise (n=50)

Allocated to Immediate Exercise (n=54)
6 months

Lost to follow-up (n = 13)

Discontinued intervention (n = 6)
Injury (unrelated) (n = 2)
Moved overseas (n = 1)
Holidays (n = 1)
Wanted to exercise at home instead (n = 1)
Health Issues (n = 1)

Health issues (n = 6)
Wanted to begin exercising (n = 3)
No longer interested (n = 2)
Fatigue from radiotherapy and working full time (n = 1)
Holidays (n = 1)
12 months
Discontinued intervention (n = 5)

Lost to follow-up (n = 1)

No longer interested (n = 2)

Didn’t return messages (n = 1)

Family issues (n = 1)
Work commitments (n = 1)
Health Issues (n = 1)

Analysed ITT (n=54)

Analysed ITT (n=50)

Western Australia. Sessions were conducted in small groups
of 6–10 participants supervised by accredited exercise
physiologists. The sessions were ~60 min in duration and
consisted of a combination of impact loading, aerobic and
resistance exercise. The frequency of aerobic and resistance
exercise was alternated weekly such that two aerobic/impact
loading and one resistance/impact loading session were
performed in 1 week and two resistance/impact loading and
one aerobic/impact loading session were performed in the
subsequent week. Detailed description of the exercise
programme and progression is described elsewhere [24].
Brieﬂy, the impact-loading component consisted of a series of
bounding (over soft hurdles), hopping, skipping, leaping, and
drop jumping activities that resulted in peak ground reaction
forces of 3.4–5.2 times body weight, with the volume and
intensity progressive in nature. For the ﬁrst 8 weeks, two

rotations were performed of skipping (30 s), bounding
(15 cm hurdles), and jumping (10 times), with jumping
replaced in weeks 5–8 by drop jumping (15 cm, 10 times).
For the second 8 weeks, three rotations were performed of
bounding (15–30 cm hurdles), drop jumping (15–20 cm, 10
times), and skipping (30 s), with skipping replaced in weeks
13–16 by hopping/leaping (10 times). Thereafter, four
rotations of hopping/leaping (10 times), bounding (30 cm
hurdles), and drop jumping (20 cm, 10 times) were
performed. Resistance training consisted of upper and lower
body exercises for the main muscle groups and included the
leg press, leg extension, leg curl, chest press, seated row, lat
pulldown, and biceps curl. Intensity was set at 6–12 repetition
maximum (RM; the maximal weight lifted 6–12 times) using
2–4 sets/exercise. The aerobic-based component consisted of
various modes and included walking/jogging on a treadmill
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and cycling or rowing on a stationary ergometer at an
intensity of 60–85% estimated maximum heart rate for 25–
40 min, with heart rate monitored using heart rate watches
(Polar Electra Oy, Finland). All sessions commenced with a
warm-up comprising low-level aerobic activities and
concluded with a cooldown of stretching activities. In
addition to clinic-based exercise, the men were encouraged to
undertake twice weekly home-based training consisting of
aerobic activities such as walking or cycling and a modiﬁed
version of the impact-loading programme consisting of
hopping, leaping, and drop jumping.
Primary and secondary endpoints
The primary endpoints of lumbar spine, total hip and whole
body BMD (g/cm2) were assessed by dual X-ray
absorptiometry (DXA, Hologic Discovery A, Waltham, MA,
USA). The Instant Vertebral Assessment and Quantitative
Morphometry program was used to determine the presence
or absence of vertebral fractures before initiation of the study.
Secondary endpoints included soft-tissue composition and
muscle density. Whole body LM and FM, percentage fat,
trunk FM, and appendicular skeletal muscle (ASM) were
derived from the whole body DXA scan, with ASM the sum
of upper- and lower-limb bone-free LM [25]. Muscle density
of the lower leg was determined by peripheral quantitative
CT (XCT3000, Stratec, Pforzheim, Germany), with
measurement and analysis undertaken at the tibia 66% site.
Other measures
Demographic and clinical data were collected by self-report
and medical records, respectively. Height and weight were
assessed using a stadiometer and electronic scales,
respectively, with body mass index (BMI, kg/m2) calculated
from weight in kg divided by height in metres squared.
Physical activity was assessed by the Leisure Score Index
(LSI) of the Godin Leisure-Time Exercise Questionnaire [26].
Testosterone and PSA, and markers of bone formation
[procollagen type 1 N-terminal propeptide (P1NP) and
alkaline phosphatase (ALP)], and bone resorption [Nterminal telopeptide of type 1 collagen (NTX)] were
measured commercially by an accredited Australian National
Association of Testing Authorities (NATA) laboratory
(Pathwest Diagnostics, Perth, WA, Australia). Exercise
intensity of each training session was assessed using Borg’s
Rating of Perceived Exertion (RPE) 6–20 scale [27].
Statistical analyses and sample size calculations
The sample size estimate was based on our previous study [3]
of the 36-week changes in BMD after initiation of ADT and
the projected differences between groups with the
undertaking of exercise [24], resulting in the requirement of
51 participants per group to achieve 80% power at an a level

264

of 0.05 (two-tailed). Data were analysed using the IBM
Statistical Package for the Social Sciences (SPSSâ) version 24
(SPSS Inc., IBM Corp., Armonk, NY, USA). Normality of the
distribution was assessed using the Kolmogorov–Smirnov test.
Between-group differences in baseline characteristics were
assessed using independent t-tests or the Mann–Whitney Utest, as appropriate, for continuous data and chi-squared for
categorical data, and a two-way (group 9 time) repeatedmeasures ANOVA for change over time (baseline, 6 and
12 months) in the primary and secondary outcome variables.
FM was not normally distributed and was log transformed
(ln) for analysis. Follow-up tests were performed if the
interaction or main effect for time was signiﬁcant. Where
appropriate, the Bonferroni post hoc procedure for multiple
comparisons was used to locate the source of the signiﬁcant
differences. Intention-to-treat was used for analyses of
primary and secondary endpoints using maximum-likelihood
imputation of missing values (expectation maximisation).
Freidman’s ANOVA with Bonferroni-adjusted Wilcoxon signedranked test, as the follow-up test, was used for other
measures. Tests were two-tailed with statistical signiﬁcance set
at an a level of 0.05.

Results
There were no signiﬁcant differences between groups at
baseline (Table 1). The men were aged 48–84 years with a
mean (SD) BMI of 27.9 (4.2) kg/m2, most were married, nonsmokers, with one or more comorbidities, and classed as
insufﬁciently physically active based on the Godin LSI. Based
on spine and/or hip BMD, 42 patients (77.8%) in the IMEX
group and 34 (68.0%) in the DEL group had normal bone
densities, 11 (20.4%) in the IMEX group and 15 (30.0%) in
the DEL group were osteopaenic, and one (1.9%) in the
IMEX group and one (2.0%) in the DEL group were
osteoporotic (P = 0.521). Baseline measures were undertaken
between 1 and 15 days, with a mean of 6 days after the ﬁrst
treatment injection (Lucrin or Zoladex). In the ﬁrst 6 months
of the study, six men in the IMEX group and 13 in the DEL
group withdrew from the study, with an additional six men
by 12 months for a total of 25 men withdrawing from the
study (Fig. 1). In addition, during the initial 6 months, 10
men in the IMEX group and ﬁve in the DEL group ceased
ADT and 40 men in the IMEX group and 30 in the DEL
group commenced radiation treatment (RT). Of the men
undergoing RT, the treatment regimen for 11 men in the
IMEX group and eight in the DEL group continued into the
initial portion of the second 6-month period. During months
7–12, an additional 19 men from the IMEX group and 17
from the DEL group ceased ADT, whilst one man in the
IMEX group recommenced ADT. For RT during this time
period, four additional men in the IMEX group and two in
the DEL group initiated treatment, whilst eight men in the
IMEX group and four in the DEL group who previously had
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external beam RT underwent brachytherapy. At 6 months,
there was no signiﬁcant difference in PSA levels between
those who ceased ADT and those who remained on
treatment [ADT, median (interquartile range, IQR) PSA level
of 0.07 (0.0–0.3) ng/mL; non-ADT, 0.04 (0.0–0.2) ng/mL;
P = 0.868], although the testosterone level was higher for
those ceasing ADT (ADT, median (IQR) testosterone level of
0.5 (0.4–0.7) nmol/L; non-ADT, 0.9 (0.5–15.8) nmol/L;
P = 0.009]. At 12 months, there remained no signiﬁcant
difference in PSA levels (ADT, median (IQR) PSA level of
0.02 (0.0–0.1) ng/mL; non-ADT, 0.04 (0.0–0.2) ng/mL;
P = 0.497]; however, the testosterone level was signiﬁcantly
greater in those not on ADT (ADT, median (IQR)
testosterone level of 1.0 (0.5–8.2) nmol/L; non-ADT, 7.8 (3.2–
14.5) nmol/L; P = 0.001]. At 6 months of ADT in the DEL
group there was a loss in BMD (spine 1.6%, hip 1.1%,
whole body 1.0%), LM ( 1.4%), ASM ( 2.5%), and muscle
density ( 1.5%), and an increase in FM (6.5%), trunk FM
(5.7%), and percentage fat (5.6%). Patients in the IMEX
group attended 79% of the scheduled exercise sessions and
those in the DEL group attended 69% of the scheduled
sessions.
BMD
There were no differences between groups for spine (P =
0.292), hip (P = 0.625) or whole body BMD (P = 0.228) at
baseline. Over the 12-month study period, there was no
signiﬁcant interaction but a signiﬁcant effect of time
(P ≤ 0.001) at the spine, hip, and whole body (Table 2).
Spine BMD decreased at 12 months compared with baseline
in both the IMEX and DEL groups; however, the BMD was
largely preserved by exercise in both groups such that at
6 months, the change in the IMEX group was 0.4%
compared with 1.6% in the DEL group, and in the second
6-month period when the DEL group exercised and the
IMEX group did not engage in the exercise programme the
changes were 0.3% and 2.2%, respectively. As a result, over
the 12-month period, the loss in both groups was similar at
1.5% in the IMEX group and 1.3% in the DEL group. For
the total hip and whole body, there was a progressive
decrease in BMD in both groups, such that by 12 months,
the loss at the hip was 2.1% and 2.3% in the IMEX and
DEL groups, respectively, and 1.4% for the whole body.
Soft-tissue composition and muscle density
There were no differences between groups for soft-tissue
composition or muscle density at baseline (P = 0.159–0.897).
IMEX preserved LM and ASM; there was a signiﬁcant time
effect (P < 0.001) for LM with no change between baseline
and 6 months, whilst it was reduced in the DEL group by
0.8 kg at 6 months and then recovered (1.4 kg) with

training during months 7–12, such that by 12 months, it was
1.4% and 1.1% higher in the IMEX and DEL groups,
respectively (Table 3). For ASM, there was a group 9 time
interaction (P = 0.009) with no signiﬁcant change over
12 months in the IMEX group but with the 12-month
measure (after training) in the DEL group greater than at
baseline and 6 months. The net differences in ASM compared
with baseline in the IMEX and DEL groups at 12 months
were 1.3% and 0.8%, respectively. There was a signiﬁcant
effect of time (P = 0.016) on muscle density, which was
preserved in the IMEX group at 6 months and reduced in the
DEL group by 1.5%. For FM, there was a signiﬁcant time
effect (P < 0.001), with FM progressively increasing in the
IMEX group by 1 kg at 6 months and a further 0.9 kg at
12 months, but in the DEL group increasing during the nonexercise period by 1.7 kg with no change thereafter with
training. As a result, body fat percentage was greater at 6 and
12 months in both groups compared with baseline. There was
a signiﬁcant interaction (P = 0.025) for trunk FM, with little
change between baseline and 6 months in the IMEX group
but at 12 months greater than baseline; whilst in the DEL
group, 6 and 12 months were greater than baseline, with no
signiﬁcant change in trunk FM in the DEL group after
training. The net change in trunk FM over the 12-month
study period in both the IMEX and DEL groups was 0.6 kg.
Other measures and adverse events
After initiation of ADT, the PSA level was reduced
(P < 0.001) to negligible levels at 6 [IMEX group, median
(IQR) PSA level of 0.1 (0.0–0.2) ng/mL; DEL group, 0.1 (0.0–
0.4) ng/mL] and 12 months [IMEX group, median (IQR)
PSA level of 0.0 (0.0–0.1) ng/mL; DEL group, 0.1 (0.0–
0.2) ng/mL], as was the testosterone level at 6 months
(P < 0.001) [IMEX group, median (IQR) testosterone level of
0.5 (0.5–0.7) nmol/L; DEL group, 0.5 (0.4–0.7) nmol/L] but
not at 12 months when recovery took place due to a number
of patients ceasing hormone treatment [IMEX group, median
(IQR) testosterone level 6.4 (0.6–11.8) nmol/L; DEL group,
7.1 (1.0–13.5) nmol/L]. Physical activity level based on the
Godin LSI increased (P = 0.001) at 6 and 12 months in the
IMEX group, and there was a signiﬁcant change in the DEL
group (P = 0.033), although this was not detected in post hoc
testing. There was also an increase in markers of bone
turnover (P < 0.001) over the 12-month period in the IMEX
and DEL groups. P1NP progressively increased at 6 and 12
months in both groups, ALP signiﬁcantly increased in the
IMEX and DEL groups by 12 months, and NTX increased in
both groups at 6 months with a further increase in the DEL
group by 12 months. The mean (range) RPE of the training
sessions was 13.3 (12.1–17.80), indicating ‘somewhat hard’ to
‘very hard’. There were no major adverse events related to the
training programme.
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Table 1 Participant characteristics.
Variable

IMEX group

Number of patients
Mean (SD):
Age, years
Height, cm
Weight, kg
BMI, kg/m2
Gleason score
N (%):
Married
Currently employed
Tertiary education
Current smoker
Number of medications, mean (SD)
Median (IQR):
Godin LSI
PSA level, ng/mL
Testosterone level, nmol/L
PINP, lg/L
ALP, U/L
NTX, nmol BCE/mmol creatine
Time since ADT injection, days, mean (SD)
N (%):
Prostatectomy
RT
Other conditions
Cardiovascular disease
Hypertension
Dyslipidaemia
Diabetes

P

DEL group

54

50

69.0
173.4
82.9
27.5
7.6

(6.3)
(7.1)
(16.4)
(4.4)
(1.0)

67.5
172.7
84.6
28.3
7.6

(7.7)
(6.2)
(12.9)
(3.9)
(0.8)

0.266
0.602
0.551
0.282
0.829

42
13
13
5
3.7

(77.8)
(24.1)
(24.1)
(9.3)
(2.3)

41
17
11
3
3.6

(82.0)
(34.0)
(22.0)
(6.0)
(2.6)

0.914
0.264
0.802
0.533
0.955

(0.0–27.0)
(0.2–10.0)
(1.9–15.8)
(27.5–52.0)
(58.8–83.5)
(26.0–42.0)
(1.9)

0.872
0.599
0.413
0.060
0.171
0.095
0.110

10.0
3.4
8.0
31.0
61.5
29.0
6.4

(0.0–24.5)
(0.7–6.4)
(2.0–16.0)
(22.0–40.0)
(51.8–78.3)
(24.0–37.0)
(2.1)

10.0
3.9
4.6
36.0
68.0
32.0
5.7

15 (27.7)
4 (7.4)

17 (34.0)
3 (6.0)

0.532
0.775

11
28
26
11

10
30
25
8

0.885
0.403
0.771
0.564

(21.1)
(51.9)
(48.1)
(20.4)

(20.0)
(60.0)
(50.0)
(16.0)

BCE, bone collagen equivalents. A moderate to strenuous LSI score of ≥24 classed as ‘active’ and ≤23 classed as ‘insufﬁciently active’.

Table 2 Regional and whole body BMD at baseline, 6 and 12 months.

Lumbar spine, g/cm2
IMEX
DEL
Total hip, g/cm2
IMEX
DEL
Whole body, g/cm2
IMEX
DEL

P

Baseline (0),
mean (SD)

6 months,
mean (SD)

12 months,
mean (SD)

1.193 (0.197)
1.154 (0.173)

1.188 (0.194)
1.136 (0.175)

1.175 (0.185)
1.139 (0.176)

0.001

0.111

0 > 12
0 > 12

1.013 (0.145)
1.000 (0.122)

1.002 (0.141)
0.989 (0.130)

0.992 (0.143)
0.977 (0.122)

<0.001

0.848

0 > 6 > 12
0 > 6 > 12

1.189 (0.115)
1.161 (0.121)

1.179 (0.116)
1.149 (0.118)

1.172 (0.110)
1.144 (0.117)

<0.001

0.827

0 > 6 > 12
0 > 6 > 12

Time

Group 3 time

Comparison*,
months

*Within-group multiple comparisons for baseline (0), 6 and 12 months, with a Bonferroni-corrected P < 0.05.

Discussion
The present year-long trial comparing immediate (initial
6 months) vs delayed (second 6-month period) exercise in
men with prostate cancer commencing ADT produced three
important ﬁndings: (i) commencing exercise that incorporates
impact loading, resistance and aerobic training at the onset of
ADT largely preserves spinal BMD, as well as whole body
LM, ASM, and muscle density; (ii) gains in whole body and
trunk FM still occurred in patients undertaking exercise at
the onset of ADT, although they were attenuated compared
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to the delayed group; (iii) by 12 months, the beneﬁts from
immediate exercise did not persist such that there were no
differences between those undergoing immediate or delayed
exercise for BMD, muscle mass or muscle quality, or for FM.
It is now becoming well recognised that exercise is beneﬁcial
for patients with cancer [28–30], with the objectives and
potential beneﬁts of exercise varying across the cancer
continuum [31]. Moreover, men with prostate cancer
recognise the need for integrating exercise support as part of
routine care [32]. In the present study, we examined the
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Table 3 Soft-tissue composition and muscle density at baseline, 6 and 12 months.
Baseline (0),
mean (SD)

LM, kg
IMEX
55.6 (9.0)
DEL
55.8 (7.2)
FM, kg
IMEX
24.5 (8.4)
DEL
26.1 (7.6)
Body fat, %
IMEX
29.0 (5.1)
DEL
30.4 (5.2)
ASM, kg
IMEX
23.6 (4.1)
DEL
23.9 (3.4)
Trunk FM, kg
IMEX
13.4 (5.2)
DEL
14.0 (4.5)
3
Muscle density, mg/cm
IMEX
72.6 (4.4)
DEL
72.9 (3.0)

6 months,
mean (SD)

12 months,
mean (SD)

55.6 (8.7)
55.0 (6.8)

P
Time

Group 3 time

56.4 (9.2)
56.4 (6.2)

<0.001

0.068

0, 6 < 12
6 < 0, 12

25.5 (8.0)
27.8 (7.1)

26.4 (8.2)
27.8 (7.5)

<0.001†

0.101†

12 > 6 > 0
6, 12 > 0

29.4 (4.7)
32.1 (4.6)

30.4 (4.6)
31.6 (4.7)

<0.001

0.013

6, 12 > 0
6, 12 > 0

23.6 (3.9)
23.3 (3.3)

23.9 (4.3)
24.1 (3.1)

<0.001

0.009

13.7 (4.9)
14.8 (4.2)

14.0 (5.0)
14.6 (4.3)

<0.001

0.025

72.3 (5.1)
71.8 (3.4)

72.0 (4.7)
72.3 (3.6)

0.016

0.107

Comparison*, months

0, 6 < 12
12 > 0
6, 12 > 0

0>6
†

*Within-group multiple comparisons for baseline (0), 6 and 12 months, with a Bonferroni-corrected P < 0.05. Statistical analysis based on log-transformed data.

timing of exercise for patients on hormone suppression
treatment, with the goal of preventing or attenuating adverse
effects on bone and body composition by undertaking
exercise at the initiation of treatment instead of exercise being
of rehabilitative intent after the development of treatmentrelated adverse effects. To this end, prescribing exercise at the
onset of ADT mitigated or attenuated musculoskeletal adverse
effects. The decline in BMD at the clinically relevant site of
the spine was attenuated, although this was not the case at
the hip (also a clinically relevant site), or the whole body
where the loss in the IMEX and DEL groups was similar.
In somewhat of a similar fashion, Winters-Stone et al. [20]
reported some preservation of BMD at L4 in men with
prostate cancer on established regimens of ADT (~2–3 years)
undertaking a year-long combined impact loading and
resistance training programme compared to usual care, with
no effect at the hip. In the only other RCT in this patient
group, Uth et al. [21], using recreational football (soccer) as a
skeletal loading stimulus in men undergoing ADT, reported
that 32-week training resulted in an increase in BMD at the
total hip of ~1%, which was signiﬁcantly different to the
control group, whilst the increase at the lumbar spine of 0.6%
was not statistically different to the non-exercisers. It is likely
that the frequent accelerations and decelerations and changes
in direction with football provide a novel osteogenic stimulus
at the hip in this patient group [21]. In a recent meta-analysis
of exercise in patients with cancer, a subgroup analysis
indicated a positive beneﬁt of combined resistance and
impact exercise on lumbar spine BMD but not at the hip
[33], which likely reﬂects both the site-speciﬁc loading
characteristics and the higher bone turnover rate at the spine
due to a greater proportion of trabecular bone [34]. With

exercise, the DEL group similarly preserved their spine BMD
between 6 and 12 months, whereas, with cessation of the
structured exercise programme the IMEX group lost 2.2% in
BMD during this period. For the whole body, given the sitespeciﬁc adaptive response of bone to an appropriate stimulus
[35], it is not surprising that no change was detected in the
IMEX or DEL groups over the 12-month period as is often
seen with resistance or resistance and impact loading exercise
in the adult population without cancer [36–38].
However, concurrently initiating exercise with androgen
suppression preserved whole body LM and ASM. In
comparison, with 6 months of ADT, the delayed group lost
0.8 kg in whole body LM and 0.6 kg in ASM. Preventing the
loss in skeletal muscle is clinically relevant, as the development
of sarcopaenia is related to falls and fractures, disability,
reduced ability to perform daily tasks and loss of independence
[39,40], and mortality in patients with cancer [41]. However,
with training, the loss incurred by DEL was recouped by
12 months, such that little difference existed at this time point
between those where exercise was initiated as a preventative
strategy or with rehabilitative intent. There was also a modest
decline in muscle density with ADT, which was attenuated with
exercise in the IMEX group, with the loss in the DEL group
partially recouped once training was undertaken, so that there
was no difference between groups at 12 months. The
signiﬁcance of a decline in muscle density in this patient
population is unclear, although in the elderly population, lower
muscle attenuation is associated with hip fracture risk, insulin
resistance, and mobility loss [12,42,43]. As in the present study,
exercise that contains a resistance training component appears
to be an effective strategy in the non-cancer population to
counter declines in muscle density [44].
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FM was not as responsive to exercise as muscle mass, with at
best an attenuation of the increase in whole body FM and
trunk FM in the IMEX group, such that instead of a 6.5%
and 5.7% increase that occurred in the DEL group the gains
at 6 months were only 4.1% and 2.2%, respectively.
Interestingly, with exercise in the DEL group, there were no
further gains in whole body FM and trunk FM, whilst gains
continued to occur in the IMEX group without supervised
training. An increase in abdominal obesity in men
undergoing ADT is associated with increased metabolic and
cardiovascular disease risk, which may result in
cardiovascular mortality [45]. Moreover, the combined effects
of preserving muscle mass and attenuating the increase in FM
may be important in preventing the development of
sarcopaenic obesity, where sarcopaenia and obesity coexist
and are associated with surgical complications, disability, and
mortality in those with cancer [46].
The present study has several strengths and limitations that
are worthy of comment. This is the ﬁrst study to compare the
timing of exercise to counter ADT treatment-related adverse
effects, that is, exercise initiated with prevention as the goal
vs exercise with rehabilitative intent. We examined the
clinically relevant fracture sites of the spine and hip, as well
as whole body BMD, and in addition to muscle mass, we
examined muscle quality. However, a number of men also
underwent RT during the initial 6-month period, as well as
the second 6-month period (a result of patients being referred
from radiation oncologists) and this may have inﬂuenced the
outcomes. In addition, although patients were to remain on
ADT for at least 6 months, some patients ceased therapy
during the initial 6 months and others during the second 6month period, which is reﬂected in changes in testosterone
levels with testosterone recovery taking place by 12 months,
which may have also inﬂuenced the outcomes. Nevertheless,
this also represents what occurs in clinical practice where
treatments will vary based on patient responses and disease
characteristics/progression. Lastly, our exclusion criteria
included men with established metastatic disease. As a result,
our present results do not apply to men with metastatic
disease; however, we have recently reported on the ﬁndings
from an exercise trial in men with bone metastases that
utilised a modular multimodal exercise programme that
resulted in the preservation of physical function with no
adverse skeletal complications [47].
In conclusion, implementing exercise in patients with prostate
cancer initiating ADT largely preserves spinal BMD, as well
as muscle mass and muscle quality, thereby offsetting
treatment-related musculoskeletal toxicities. Consequently,
although undertaking exercise with rehabilitative intent after
ADT-related adverse effects occur is beneﬁcial for the patient
with prostate cancer, exercise medicine at the onset of
treatment should be prescribed in order to prevent or
attenuate the development of musculoskeletal toxicities.
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